Trial Profile

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorigerlimab (Primary)
Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Therapeutic Use
Acronyms LINNET
Sponsors MacroGenics

Most Recent Events

23 Jul 2026 According to a MacroGenics media release, company plans to present data including patients with advanced gynecologic cancers from this study at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain.
02 Jun 2026 Planned End Date changed from 1 Aug 2027 to 1 Dec 2027.
02 Jun 2026 Planned primary completion date changed from 1 Feb 2027 to 1 Jul 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com